Market Bounce Expected to be Short-Lived Amid Downside Risks
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 23 2026
0mins
Should l Buy OPY?
Source: CNBC
- Market Bounce: Following President Trump's 'productive' talks with Iran, the S&P 500 surged 1.2% on Monday, with futures rallying as much as 4.1%, yet analysts caution that this rebound may be short-lived.
- Technical Indicator Analysis: The S&P 500 has fallen below its 200-day moving average, with analysts suggesting that while a near-term bounce could push it back to 6,900, the longer-term trend indicates significant downside risks ahead.
- Investor Sentiment: Analysts at BTIG argue that investors remain complacent, with the S&P 500 facing a potential drop to 6,000, representing a 7% decline from Friday's close, indicating ongoing market vulnerability.
- Small-Cap Performance: The Russell 2000 index has entered correction territory with a drop exceeding 10%, while the Nasdaq Composite and Dow Jones Industrial Average also experienced intraday declines of over 10% on Friday, highlighting the fragility of the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy OPY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on OPY
About OPY
Oppenheimer Holdings Inc., through its subsidiaries, is a middle market investment bank and full-service broker-dealer. The Company is engaged in a broad range of activities in the financial services industry, including retail securities brokerage, institutional sales and trading, investment banking (corporate and public finance), equity and fixed income research, market-making, trust services, and investment advisory and asset management services. The Company’s Wealth Management segment provides a comprehensive array of financial services through a network of financial advisors. Its wealth management services include full-service brokerage, wealth planning, and margin lending. Its Capital Markets segment includes investment banking, institutional equities sales, trading, and research, taxable fixed income sales, trading, and research, public finance and municipal trading, as well as the Company's operations in the United Kingdom, Hong Kong and Israel.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Centessa Pharmaceuticals Acquired by Eli Lilly for Up to $7.8 Billion
- Acquisition Overview: Centessa Pharmaceuticals has entered into an acquisition agreement with Eli Lilly for up to $7.8 billion, with a cash purchase price of $38 per share representing a nearly 38% premium over Monday's closing price, indicating strong market confidence in its potential.
- Drug Development Prospects: Centessa is developing a novel class of drugs, specifically orexin receptor 2 (OX2R) agonists targeting daytime sleepiness and other neurological conditions, with its most promising drug, cleminorexton, showing best-in-class potential in Phase 2 clinical trials, positioning it as a market leader.
- Market Potential Analysis: According to Oppenheimer, Centessa's experimental therapies could capture a significant share of the $20 billion market for severe sleep disorder treatments, further enhancing Eli Lilly's strategic diversification of its development pipeline.
- Regulatory and Shareholder Approval: The transaction is projected to close in the third quarter, subject to shareholder and regulatory approval, and upon completion, Centessa's shareholders will receive a non-transferrable contingent value right valued at up to $9 per share.
See More
Centessa Pharmaceuticals Acquired by Eli Lilly for Up to $7.8 Billion
- Acquisition Overview: Eli Lilly is acquiring Centessa Pharmaceuticals for up to $7.8 billion, offering $38 per share in cash, which represents a nearly 38% premium over Centessa's closing price on Monday, providing substantial returns for its investors.
- Contingent Value Rights: Centessa shareholders will also receive a non-transferable contingent value right that could be worth up to $9 per share if certain regulatory milestones for its investigational drugs are met, enhancing the attractiveness and potential profitability of the deal.
- Market Potential Analysis: Centessa is developing a novel class of drugs targeting daytime sleepiness and other neurological conditions, with its leading experimental drug, cleminorexton, showing best-in-class potential in Phase 2 clinical studies, which could position it well in a $20 billion market for severe sleep disorder treatments.
- Strategic Investment Intent: Eli Lilly is leveraging the profits from its successful GLP-1 drugs, Mounjaro and Zepbound, to diversify its development pipeline, with Centessa's experimental therapies poised to become blockbuster sellers, further solidifying Lilly's leadership in the neuroscience sector.
See More
Latest Wall Street Rating Updates
- UBS Upgrade: UBS upgrades Adecoagro from Neutral to Buy, raising the price target from $8 to $16.2, indicating the company is poised to benefit from the ongoing Middle East conflict, which is expected to enhance its financial performance.
- HSBC Bullish on Carnival: HSBC upgrades Carnival from Hold to Buy, asserting that the current share price undervalues the resilience of experience-led demand, which is likely to improve the company's market performance in the near future.
- Morgan Stanley Reiterates Meta: Morgan Stanley lowers its price target for Meta from $825 to $775 but maintains it as a top investment idea, suggesting that market sentiment has bottomed out, making it an opportune time to buy.
- Deutsche Bank Upgrades Colgate: Deutsche Bank upgrades Colgate-Palmolive from Hold to Buy, highlighting the company's core business as having long-term investment value and the ability to weather current market volatility effectively.
See More
Peter Bennett to Lead Corporate Executive Services Team
- Leadership Changes: Oppenheimer has appointed Chris DeFalco and John Hyland as Co-Heads of the Equity Capital Markets Investment Banking group, aiming to drive continued growth by deepening product expertise and enhancing competitiveness in core industries.
- Functional Integration: Peter Bennett will transition from Head of Equity Capital Markets to lead the Corporate Executive Services team, focusing on strengthening connectivity between Investment Banking and Wealth Management to provide a more coordinated client experience, reflecting the firm's commitment to evolving client needs.
- Experienced Team: DeFalco, who joined in 2015, has completed over 285 equity and equity-linked offerings, while Hyland has played a crucial role in expanding IPOs since joining in 2021, leveraging their extensive capital markets experience to advance Oppenheimer's ECM platform.
- Strengthening Client Relationships: The new leaders emphasize a focus on consistent execution and direct dialogue with clients, aiming to support corporate leaders not only at the transaction level but also as long-term partners as their priorities evolve.
See More
Peter Bennett to Lead Corporate Executive Services Team
- Leadership Changes: Oppenheimer & Co. Inc. announced that Chris DeFalco and John Hyland have been appointed as Co-Heads of the Equity Capital Markets Investment Banking group, aiming to drive the firm's continued growth by deepening product expertise.
- Strategic Integration: Peter Bennett will transition from Head of Equity Capital Markets to lead the Corporate Executive Services team, aiming to strengthen connectivity between Investment Banking and Wealth Management, thereby providing a more coordinated client experience.
- Industry Expertise: Since joining in 2015, DeFalco has completed over 285 equity and equity-linked offerings as bookrunner or lead manager, showcasing his expertise in the consumer, healthcare, and technology sectors.
- Capability Expansion: Hyland, who joined in 2021, has successfully driven Oppenheimer's IPO expansion across consumer, financial institutions, industrials, and technology, bringing over 20 years of capital markets experience and participating in over 200 equity offerings, further solidifying the firm's market position.
See More
Market Bounce Expected to be Short-Lived Amid Downside Risks
- Market Bounce: Following President Trump's 'productive' talks with Iran, the S&P 500 surged 1.2% on Monday, with futures rallying as much as 4.1%, yet analysts caution that this rebound may be short-lived.
- Technical Indicator Analysis: The S&P 500 has fallen below its 200-day moving average, with analysts suggesting that while a near-term bounce could push it back to 6,900, the longer-term trend indicates significant downside risks ahead.
- Investor Sentiment: Analysts at BTIG argue that investors remain complacent, with the S&P 500 facing a potential drop to 6,000, representing a 7% decline from Friday's close, indicating ongoing market vulnerability.
- Small-Cap Performance: The Russell 2000 index has entered correction territory with a drop exceeding 10%, while the Nasdaq Composite and Dow Jones Industrial Average also experienced intraday declines of over 10% on Friday, highlighting the fragility of the market.
See More
Centessa Pharmaceuticals Acquired by Eli Lilly for Up to $7.8 Billion
- Acquisition Overview: Centessa Pharmaceuticals has entered into an acquisition agreement with Eli Lilly for up to $7.8 billion, with a cash purchase price of $38 per share representing a nearly 38% premium over Monday's closing price, indicating strong market confidence in its potential.
- Drug Development Prospects: Centessa is developing a novel class of drugs, specifically orexin receptor 2 (OX2R) agonists targeting daytime sleepiness and other neurological conditions, with its most promising drug, cleminorexton, showing best-in-class potential in Phase 2 clinical trials, positioning it as a market leader.
- Market Potential Analysis: According to Oppenheimer, Centessa's experimental therapies could capture a significant share of the $20 billion market for severe sleep disorder treatments, further enhancing Eli Lilly's strategic diversification of its development pipeline.
- Regulatory and Shareholder Approval: The transaction is projected to close in the third quarter, subject to shareholder and regulatory approval, and upon completion, Centessa's shareholders will receive a non-transferrable contingent value right valued at up to $9 per share.
See More
Centessa Pharmaceuticals Acquired by Eli Lilly for Up to $7.8 Billion
- Acquisition Overview: Eli Lilly is acquiring Centessa Pharmaceuticals for up to $7.8 billion, offering $38 per share in cash, which represents a nearly 38% premium over Centessa's closing price on Monday, providing substantial returns for its investors.
- Contingent Value Rights: Centessa shareholders will also receive a non-transferable contingent value right that could be worth up to $9 per share if certain regulatory milestones for its investigational drugs are met, enhancing the attractiveness and potential profitability of the deal.
- Market Potential Analysis: Centessa is developing a novel class of drugs targeting daytime sleepiness and other neurological conditions, with its leading experimental drug, cleminorexton, showing best-in-class potential in Phase 2 clinical studies, which could position it well in a $20 billion market for severe sleep disorder treatments.
- Strategic Investment Intent: Eli Lilly is leveraging the profits from its successful GLP-1 drugs, Mounjaro and Zepbound, to diversify its development pipeline, with Centessa's experimental therapies poised to become blockbuster sellers, further solidifying Lilly's leadership in the neuroscience sector.
See More
Latest Wall Street Rating Updates
- UBS Upgrade: UBS upgrades Adecoagro from Neutral to Buy, raising the price target from $8 to $16.2, indicating the company is poised to benefit from the ongoing Middle East conflict, which is expected to enhance its financial performance.
- HSBC Bullish on Carnival: HSBC upgrades Carnival from Hold to Buy, asserting that the current share price undervalues the resilience of experience-led demand, which is likely to improve the company's market performance in the near future.
- Morgan Stanley Reiterates Meta: Morgan Stanley lowers its price target for Meta from $825 to $775 but maintains it as a top investment idea, suggesting that market sentiment has bottomed out, making it an opportune time to buy.
- Deutsche Bank Upgrades Colgate: Deutsche Bank upgrades Colgate-Palmolive from Hold to Buy, highlighting the company's core business as having long-term investment value and the ability to weather current market volatility effectively.
See More
Peter Bennett to Lead Corporate Executive Services Team
- Leadership Changes: Oppenheimer has appointed Chris DeFalco and John Hyland as Co-Heads of the Equity Capital Markets Investment Banking group, aiming to drive continued growth by deepening product expertise and enhancing competitiveness in core industries.
- Functional Integration: Peter Bennett will transition from Head of Equity Capital Markets to lead the Corporate Executive Services team, focusing on strengthening connectivity between Investment Banking and Wealth Management to provide a more coordinated client experience, reflecting the firm's commitment to evolving client needs.
- Experienced Team: DeFalco, who joined in 2015, has completed over 285 equity and equity-linked offerings, while Hyland has played a crucial role in expanding IPOs since joining in 2021, leveraging their extensive capital markets experience to advance Oppenheimer's ECM platform.
- Strengthening Client Relationships: The new leaders emphasize a focus on consistent execution and direct dialogue with clients, aiming to support corporate leaders not only at the transaction level but also as long-term partners as their priorities evolve.
See More
Peter Bennett to Lead Corporate Executive Services Team
- Leadership Changes: Oppenheimer & Co. Inc. announced that Chris DeFalco and John Hyland have been appointed as Co-Heads of the Equity Capital Markets Investment Banking group, aiming to drive the firm's continued growth by deepening product expertise.
- Strategic Integration: Peter Bennett will transition from Head of Equity Capital Markets to lead the Corporate Executive Services team, aiming to strengthen connectivity between Investment Banking and Wealth Management, thereby providing a more coordinated client experience.
- Industry Expertise: Since joining in 2015, DeFalco has completed over 285 equity and equity-linked offerings as bookrunner or lead manager, showcasing his expertise in the consumer, healthcare, and technology sectors.
- Capability Expansion: Hyland, who joined in 2021, has successfully driven Oppenheimer's IPO expansion across consumer, financial institutions, industrials, and technology, bringing over 20 years of capital markets experience and participating in over 200 equity offerings, further solidifying the firm's market position.
See More
Market Bounce Expected to be Short-Lived Amid Downside Risks
- Market Bounce: Following President Trump's 'productive' talks with Iran, the S&P 500 surged 1.2% on Monday, with futures rallying as much as 4.1%, yet analysts caution that this rebound may be short-lived.
- Technical Indicator Analysis: The S&P 500 has fallen below its 200-day moving average, with analysts suggesting that while a near-term bounce could push it back to 6,900, the longer-term trend indicates significant downside risks ahead.
- Investor Sentiment: Analysts at BTIG argue that investors remain complacent, with the S&P 500 facing a potential drop to 6,000, representing a 7% decline from Friday's close, indicating ongoing market vulnerability.
- Small-Cap Performance: The Russell 2000 index has entered correction territory with a drop exceeding 10%, while the Nasdaq Composite and Dow Jones Industrial Average also experienced intraday declines of over 10% on Friday, highlighting the fragility of the market.
See More
